← Every company
Amylyx Pharmaceuticals Inc Patents
What Amylyx Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
AMLX on carbonthat →Filings on file
34
Granted
0
Still pending
34
Filed under
3 names
34 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| COMPOSITIONS AND METHODS FOR TREATING SUBJECTS WITH RENAL IMPAIRMENTA61K 31/575, A61P 13/12, A61K 31/192Filed as Amylyx Pharmaceuticals, Inc.2026-03-03Marcelo Menchavez Gutierrez | pending |
| LIVER X RECEPTOR AGONISTS, COMPOSITIONS AND METHODSFiled as AMYLYX PHARMACEUTICALS, INC.2025-12-18JOSHUA B. COHEN | pending |
| TREATMENT OF POST-BARIATRIC HYPOGLYCEMIAA61K 38/26, A61P 3/08, A61K 9/0019, A61K 9/08, A61K 47/12, A61K 47/26Filed as Amylyx Pharmaceuticals, Inc.2025-12-16Robert Ryan Miller | pending |
| CHI3L1-TARGETING OLIGONUCLEOTIDES AND METHODS OF USING THE SAMEFiled as AMYLYX PHARMACEUTICALS, INC.2025-12-05DUNCAN BROWN | pending |
| TREATMENT OF POST-BARIATRIC HYPOGLYCEMIAFiled as AMYLYX PHARMACEUTICALS, INC.2025-12-02ROBERT RYAN MILLER | pending |
| ANTISENSE OLIGONUCLEOTIDES TARGETING CALPAIN-2Filed as AMYLYX PHARMACEUTICALS, INC.2025-08-08JOSHUA COHEN | pending |
| FORMULATIONS CONTAINING ANTISENSE OLIGONUCLEOTIDES TARGETING CALPAIN-2Filed as AMYLYX PHARMACEUTICALS, INC.2025-08-08JOSHUA COHEN | pending |
| METHODS AND COMPOSITIONS FOR TREATING WOLFRAM SYNDROMEA61K 31/575, A61P 3/10, A61K 31/192, A61K 45/06Filed as Amylyx Pharmaceuticals, Inc.2025-04-30Joshua Cohen | pending |
| METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH LOW C-PEPTIDEFiled as AMYLYX PHARMACEUTICALS, INC.2025-03-07LAHAR MEHTA | pending |
| METHODS AND COMPOSITIONS FOR TREATING WOLFRAM SYNDROMEFiled as AMYLYX PHARMACEUTICALS, INC.2025-03-07LAHAR MEHTA | pending |
| ANTISENSE OLIGONUCLEOTIDES TARGETING CALPAIN-2Filed as Amylyx Pharmaceuticals, Inc.2025-02-11Joshua Cohen | pending |
| COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDSA61P 25/16, A61K 9/1623, A61K 31/216, A61K 31/575, A61K 45/06, A61P 25/14, A61P 9/10, A61P 25/28, A61K 9/1611, A61K 9/1652, A61K 31/192, A61K 47/02, A61K 47/26, A61K 47/36, A61K2300/00Filed as Amylyx Pharmaceuticals, Inc.2025-01-15Joshua Cohen | pending |
| LIVER X RECEPTOR AGONISTS, COMPOSITIONS AND METHODSFiled as Amylyx Pharmaceuticals, Inc.2024-12-20Joshua B. Cohen | pending |
| YKL-40 TARGETING OLIGONUCLEOTIDES AND METHODS OF USING THE SAMEFiled as Amylyx Pharmaceuticals, Inc.2024-12-06Duncan Brown | pending |
| TREATMENT OF POST-BARIATRIC HYPOGLYCEMIAFiled as Amylyx Pharmaceuticals, Inc.2024-12-02Robert Ryan Miller | pending |
| COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOFA61K 31/575, A61P 39/06, A61P 25/28, A61K 9/0053, A61K 31/192, A61K2300/00Filed as Amylyx Pharmaceuticals Inc.2024-11-19Joshua Cohen | pending |
| METHODS AND COMPOSITIONS FOR TREATING WOLFRAM SYNDROMEFiled as Amylyx Pharmaceuticals, Inc.2024-10-21Lahar Mehta | pending |
| Antisense Oligonucleotides Targeting Calpain-2Filed as Amylyx Pharmaceuticals, Inc.2024-10-17Joshua Cohen | pending |
| METHODS AND COMPOSITIONS FOR TREATING WOLFRAM SYNDROMEFiled as Amylyx Pharmaceuticals, Inc.2024-10-15Lahar Mehta | pending |
| TREATMENT OF CONGENITAL HYPERINSULINISM WITH AVEXITIDEA61K 38/26, A61P 3/08Filed as AMYLYX PHARMACEUTICALS, INC.2024-10-03Colleen M. Craig | pending |
| FORMULATION CONTAINING TAURURSODIOL AND SODIUM PHENYLBUTYRATEFiled as AMYLYX PHARMACEUTICALS, INC.2024-09-05JOSHUA BARRY COHEN | pending |
| COMPOSITIONS AND METHODS FOR TREATING SUBJECTS WITH HEPATIC IMPAIRMENTFiled as AMYLYX PHARMACEUTICALS, INC.2024-09-04MARCELO MENCHAVEZ GUTIERREZ | pending |
| COMPOSITIONS AND METHODS FOR TREATING SUBJECTS WITH RENAL IMPAIRMENTFiled as AMYLYX PHARMACEUTICALS, INC.2024-09-04MARCELO MENCHAVEZ GUTIERREZ | pending |
| ANTISENSE OLIGONUCLEOTIDES TARGETING CALPAIN-2Filed as Amylyx Pharmaceuticals, Inc.2024-08-21Mr. Joshua Cohen | pending |
| ANTISENSE OLIGONUCLEOTIDES TARGETING CALPAIN-2Filed as Amylyx Pharmaceuticals, Inc.2024-08-09Mr. Joshua Cohen | pending |
| FORMULATIONS CONTAINING ANTISENSE OLIGONUCLEOTIDES TARGETING CALPAIN-2Filed as Amylyx Pharmaceuticals, Inc.2024-08-09Joshua Cohen | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF VARIOUS DISEASESA61K 31/575, A61P 25/14, A61P 25/28, A61K 31/192, A61K2300/00Filed as Amylyx Pharmaceuticals, Inc.2024-07-23Joshua Barry Cohen | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF VARIOUS DISEASESFiled as AMYLYX PHARMACEUTICALS, INC.2024-07-23JOSHUA BARRY COHEN | pending |
| COMBINATION OF A BILE ACID AND A PHENYL BUTYRATE COMPOUND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASESFiled as Amylyx Pharmaceuticals, Inc.2024-05-06Joshua Cohen | pending |
| GLP-1R ANTAGONISM TO IMPROVE NUTRITION FOLLOWING GASTROINTESTINAL SURGERYFiled as AMYLYX PHARMACEUTICALS, INC.2024-04-22COLLEEN M. CRAIG | pending |
| METHODS AND COMPOSITIONS FOR TREATING WOLFRAM SYNDROMEFiled as Amylyx Pharmaceuticals, Inc.2024-04-09Lahar Mehta | pending |
| METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH LOW C-PEPTIDEFiled as Amylyx Pharmaceuticals, Inc.2024-03-07Lahar Mehta | pending |
| METHODS AND COMPOSITIONS FOR TREATING WOLFRAM SYNDROMEFiled as Amylyx Pharmaceuticals, Inc.2024-03-07Lahar Mehta | pending |
| METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISA61K 31/575, A61K 38/13, A61P 21/00, A61P 25/28, A61P 25/02, A61K 31/192, A61K2300/00Filed as Amylyx Pharmaceuticals, Inc.2024-02-16Joshua Cohen | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on AMLX
Company overviewEverything on AMLX in one place, with the price.SEC filingsWhat AMLX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat AMLX's own officers and directors buy and sell.Planned salesSales AMLX insiders have filed notice of.Who owns itEvery manager reporting a position in AMLX.Funds holding itWhich funds and ETFs hold AMLX, and how big a bet.LobbyingWhat AMLX spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on AMLX's account, and who they worked for.